Inspire Medical Systems (INSP) officer Jason P. Kelly sells 963 shares at $59.55

Q: What insider transaction did Inspire Medical Systems (INSP) report for Jason P. Kelly?

Jason P. Kelly reported selling 963 shares of Inspire Medical Systems common stock on 2026-08-07 at $59.55 per share . After this sale, he directly holds 18,985 shares of the company’s common stock.

Q: Was the Jason P. Kelly INSP stock sale under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as a trading plan. This means the reported sale of 963 Inspire Medical Systems shares was not affirmed as executed under a pre-arranged Rule 10b5-1 plan in this filing.

Q: What role does Jason P. Kelly hold at Inspire Medical Systems (INSP)?

Jason P. Kelly is identified as Inspire Medical Systems’ Chief Manufacturing and Quality Officer . His officer status is disclosed in the filing remarks, which describe his title in connection with the reported sale of 963 shares of common stock.

Q: Is the reported INSP transaction by Jason P. Kelly a buy or a sell?

The transaction reported by Jason P. Kelly is a sale of Inspire Medical Systems common stock. The Form 4 lists transaction code S and an acquired/disposed code indicating a disposition of 963 shares at $59.55 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Inspire Medical Systems, Inc. insider Jason P. Kelly, Chief Manufacturing and Quality Officer, reported a sale of 963 shares of common stock on 2026-08-07 at $59.55 per share. Following this open-market sale, Kelly directly holds 18,985 shares of Inspire Medical Systems common stock.

Insider Trade Summary

Net Seller: 963 shares

Net Sell 1 txn

Insider Kelly Jason P

Role See Remarks

Sold 963 shs ($57K)

Type	Security	Shares	Price	Value
Sale	Common Stock	963	$59.55	$57K

Holdings After Transaction: Common Stock — 18,985 shares (Direct)

Key Figures

Shares sold: 963 shares Sale price per share: $59.55 per share Shares owned after transaction: 18,985 shares

3 metrics

Shares sold 963 shares Common Stock sale on 2026-08-07 by Jason P. Kelly

Sale price per share $59.55 per share Price for the 963-share Common Stock sale

Shares owned after transaction 18,985 shares Directly held by Jason P. Kelly following the reported sale

Key Terms

Rule 10b5-1, open market or private transaction, Common Stock

3 terms

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not marked as a trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"Transaction code S is described as a sale in open market or private transaction."

Common Stock financial

"The reported transaction involves 963 shares of Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 07:13 PM Accepted by SEC EDGAR 08/11/2026 - 07:13 PM

FAQ

What insider transaction did Inspire Medical Systems (INSP) report for Jason P. Kelly?

Jason P. Kelly reported selling 963 shares of Inspire Medical Systems common stock on 2026-08-07 at $59.55 per share. After this sale, he directly holds 18,985 shares of the company’s common stock.

At what price were Jason P. Kelly’s INSP shares sold?

The reported sale of Inspire Medical Systems (INSP) shares by Jason P. Kelly was executed at $59.55 per share. The transaction involved 963 shares of common stock in an open market or private transaction, as characterized in the filing.

How many Inspire Medical Systems (INSP) shares does Jason P. Kelly own after the sale?

After the reported transaction, Jason P. Kelly directly owns 18,985 shares of Inspire Medical Systems common stock. This figure reflects holdings following the sale of 963 shares reported for the transaction date of 2026-08-07.

Was the Jason P. Kelly INSP stock sale under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as a trading plan. This means the reported sale of 963 Inspire Medical Systems shares was not affirmed as executed under a pre-arranged Rule 10b5-1 plan in this filing.

What role does Jason P. Kelly hold at Inspire Medical Systems (INSP)?

Jason P. Kelly is identified as Inspire Medical Systems’ Chief Manufacturing and Quality Officer. His officer status is disclosed in the filing remarks, which describe his title in connection with the reported sale of 963 shares of common stock.

Is the reported INSP transaction by Jason P. Kelly a buy or a sell?

The transaction reported by Jason P. Kelly is a sale of Inspire Medical Systems common stock. The Form 4 lists transaction code S and an acquired/disposed code indicating a disposition of 963 shares at $59.55 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Jason P

(Last)

(First)

(Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY

MINNESOTA

55416

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/07/2026		S		963	D	$59.55	18,985	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

Title - Chief Manufacturing and Quality Officer.

	/s/ Bryan Phillips, Attorney-in-Fact for Jason P. Kelly	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR